FGL1 Protein, Cynomolgus (sf9, His)
FGL1 is a specific hepatocyte mitogen, regulates the expression of proliferative factors, promoting liver regeneration and repairing liver injury. FGL1 inhibits T-cell activation by binding to LAG3. FGL1 promotes cell proliferation by activating the ERK/p-ERK pathway. FGL1 inhibits apoptosis of non-small cell lung cancer (NSCLC) cells by inhibiting PARP1/caspase 3 pathway. FGL1 Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived FGL1 protein, expressed by Sf9 insect cells , with C-His labeled tag.
- Species: Cynomolgus
- Source: Sf9 insect cells
-
Storage:Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Biological Activity
Description
FGL1 is a specific hepatocyte mitogen, regulates the expression of proliferative factors, promoting liver regeneration and repairing liver injury. FGL1 inhibits T-cell activation by binding to LAG3. FGL1 promotes cell proliferation by activating the ERK/p-ERK pathway. FGL1 inhibits apoptosis of non-small cell lung cancer (NSCLC) cells by inhibiting PARP1/caspase 3 pathway. FGL1 Protein, Cynomolgus (sf9, His) is the recombinant cynomolgus-derived FGL1 protein, expressed by Sf9 insect cells , with C-His labeled tag.
Background
Fibrin-as-protein 1, a member of the fibrinogen family, is a specific hepatocyte mitogen. FGL1 regulates the expression of proliferative factors, promotes liver regeneration and repairs liver injury. FGL1 inhibits T-cell activation by binding to LAG3. FGL1 promotes cell proliferation by activating the ERK/p-ERK pathway. FGL1 inhibits apoptosis of non-small cell lung cancer (NSCLC) cells by inhibiting PARP1/caspase 3 pathway[1][2][3].
Technical Parameters
-
Species Cynomolgus
-
Source Sf9 insect cells
-
Tag C-His
-
Accession
XP_005562748.1 (M37-I348)
-
Molecular Construction
-
N-term
-
FGL1 (M37-I348)
Accession # XP_005562748.1 -
His
-
C-term
-
-
Protein Length
Partial
-
Synonyms
FGL1; Fibrinogen-Like Protein 1; Fibrinogen Like 1; LFIRE-1; HPS; HFREP1; Hepassocin; HP-041; HFREP-1; Hepatocellular Carcinoma-Related Sequence; Hepatocyte-Derived Fibrinogen-Related Protein 1; LFIRE1; Liver Fibrinogen-Related Protein 1
-
AA Sequence
MAKMFSFILVVTALIMGRESSALEDCAQEQVRLRAQVRLLETRVKQQQVKIKQLLQENEVQFLDKGEENSVIDLGSKRQYADCSEIFNDGYKLSGFYKIKPLQSPAEFAVYCDMSDGGGWTVIQRRSDGSENFNRGWNDYENGFGNFVQKHGEYWLGNKNLHFLTTQEDYTLKIDLADFEKNSRYAQYKNFKVGDEKNFYELNIGEYSGTAGDSLAGSFHPEVQWWATHQRMKFSTWDRDHDNYDGNCAEEDQSGWWFNRCHSANLNGLYYTGPYTAKTDNGIVWYTWHGWWYSLKSVVMKIRPNDFIPNVI
-
Predicted Molecular Mass
35.4 kDa
-
Purity
≥ 90%, as determined by reducing SDS-PAGE.
Product Properties
Solution
<1 EU/μg, determined by LAL method.
Stored at -80°C for 1 year from date of receipt. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.
Shipping with dry ice.
Documentation
References
[1]. Shi AP, et al. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. Front Immunol. 2022 Jan 17;12:785091. [Content Brief]
[2]. Sun C, et al. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer. Respir Res. 2020 Aug 10;21(1):210. [Content Brief]
[3]. Sato H, et al. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer. Cancer Sci. 2018 Oct;109(10):3183-3196. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)